Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.

about

Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.

Item

http://www.wikidata.org/entity/Q38653262

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.

@en

type

Item

label

Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.

@en

prefLabel

Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.

@en

P1476

Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence.

@en

P2093

Carsten Nieder

http://www.w3.org/2001/XMLSchema#string

Jan Norum

http://www.w3.org/2001/XMLSchema#string

P2860

Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature

Androgen deprivation therapy as backbone therapy in the management of prostate cancer

Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Abiraterone and increased survival in metastatic prostate cancer

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.

Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.

Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases.

P2888

s40273-017-0555-8

P31

scholarly article

P356

10.1007/S40273-017-0555-8

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28756597

http://www.w3.org/2001/XMLSchema#string